These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment. Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395 [TBL] [Abstract][Full Text] [Related]
5. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Yang YR; Liu SL; Qin ZY; Liu FJ; Qin YJ; Bai SM; Chen ZY Cell Mol Neurobiol; 2008 Aug; 28(5):737-44. PubMed ID: 18343991 [TBL] [Abstract][Full Text] [Related]
6. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Jin T; Hu LS; Chang M; Wu J; Winblad B; Zhu J Eur J Neurol; 2007 May; 14(5):563-8. PubMed ID: 17437617 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of Apolipoprotein-E and Apolipoprotein-J in Moyamoya Disease-A Proteome Analysis of Cerebrospinal Fluid. Kashiwazaki D; Uchino H; Kuroda S J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2981-2987. PubMed ID: 28843803 [TBL] [Abstract][Full Text] [Related]
8. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? Niemelä V; Landtblom AM; Blennow K; Sundblom J PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046 [TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic characteristics in patients with Huntington's disease from China. Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361 [TBL] [Abstract][Full Text] [Related]
10. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877 [TBL] [Abstract][Full Text] [Related]
11. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Li X; Miyajima M; Mineki R; Taka H; Murayama K; Arai H Acta Neurochir (Wien); 2006 Aug; 148(8):859-64; discussion 864. PubMed ID: 16755327 [TBL] [Abstract][Full Text] [Related]
12. Clinical correlates of mitochondrial function in Huntington's disease muscle. Turner C; Cooper JM; Schapira AH Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337 [TBL] [Abstract][Full Text] [Related]
14. Association of status redox with demographic, clinical and imaging parameters in patients with Huntington's disease. Peña-Sánchez M; Riverón-Forment G; Zaldívar-Vaillant T; Soto-Lavastida A; Borrero-Sánchez J; Lara-Fernández G; Esteban-Hernández EM; Hernández-Díaz Z; González-Quevedo A; Fernández-Almirall I; Pérez-López C; Castillo-Casañas Y; Martínez-Bonne O; Cabrera-Rivero A; Valdés-Ramos L; Guerra-Badía R; Fernández-Carriera R; Menéndez-Sainz MC; González-García S Clin Biochem; 2015 Dec; 48(18):1258-63. PubMed ID: 26210848 [TBL] [Abstract][Full Text] [Related]
15. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting. Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172 [TBL] [Abstract][Full Text] [Related]
16. Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington's Disease. Chang KH; Cheng ML; Lo CJ; Fan CM; Wu YR; Chen CM Cells; 2023 Jan; 12(3):. PubMed ID: 36766727 [TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. Ruocco HH; Bonilha L; Li LM; Lopes-Cendes I; Cendes F J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):130-5. PubMed ID: 17615168 [TBL] [Abstract][Full Text] [Related]
19. Ideomotor limb apraxia in Huntington's disease: a case-control study. Hödl AK; Hödl E; Otti DV; Herranhof B; Ille R; Bonelli RM J Neurol; 2008 Mar; 255(3):331-9. PubMed ID: 18305889 [TBL] [Abstract][Full Text] [Related]
20. Pulmonary function in patients with Huntington's disease. Reyes A; Cruickshank T; Ziman M; Nosaka K BMC Pulm Med; 2014 May; 14():89. PubMed ID: 24886346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]